These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 19237657)

  • 1. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
    Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction.
    Wang TY; Chen AY; Alexander KP; Ohman EM; Gibler WB; Peterson ED; Roe MT
    Am J Med; 2008 Sep; 121(9):805-10. PubMed ID: 18724971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
    Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
    Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction.
    Flaker GC; Bartolozzi J; Davis V; McCabe C; Cannon CP
    Arch Intern Med; 1994 Jul; 154(13):1492-6. PubMed ID: 8018004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
    Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
    Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
    Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes.
    Melloni C; Alexander KP; Chen AY; Newby LK; Roe MT; Allen LaPointe NM; Pollack CV; Gibler WB; Ohman EM; Peterson ED;
    Am Heart J; 2008 Aug; 156(2):209-15. PubMed ID: 18657648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.